PROSPA GROUP LIMITED. - Announcements

0.00%

44.5¢

Currently unlisted. Proposed listing date: TUESDAY, 11 JUNE 2019, 12:00PM ##

Prospa Group Ltd is an Australia-based financial technology company. The Company is a... Prospa Group Ltd is an Australia-based financial technology company. The Company is a provider of cash flow products and services. The Company’s operations consist primarily of the provision of loans to small businesses in Australia and New Zealand. It facilitates referrals and customer acquisitions from a network of distribution partners, including finance brokers, aggregator networks, online affiliates, accountants and other advisers. The purpose-built credit decision engine (CDE) enables approvals and adoption of dynamic risk-based pricing, where interest rates associated with a facility are based on credit risk assessments for individual customers. Its CDE allows the business to quickly evaluate opportunities and potential risks across the portfolio. Its product suite includes a Small Business Loan and a Line of Credit. The Company has launched Prospa Plus Business Loans, offering higher credit quality for small to medium enterprises (SME).More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile

See benefits

Announcements

Filter Results

All Price Sensitive Only

PGL	Notice of Annual General Meeting/Proxy Form		31/10/11	670.8KB	Share
PGL	Appendix 3Y		25/10/11	73.11KB	Share
PGL	Progen Licensee Receives IND Approval in Korea for PI-88	PRICE SENSITIVE	17/10/11	92.63KB	Share
PGL	Non-Executive Director Resignation		30/09/11	90.3KB	Share
PGL	Annual Report to shareholders		30/09/11	3.2MB	Share
PGL	Appendix 3Y		29/09/11	70.54KB	Share
PGL	Licensee Commences Recruitment, End of Settlement Agreement	PRICE SENSITIVE	26/09/11	239.88KB	Share
PGL	Closure of PG545 Phase 1a Clinical Trial	PRICE SENSITIVE	20/09/11	93.7KB	Share
PGL	Appendix 3Z		24/08/11	71.39KB	Share
PGL	Appendix 3Z		24/08/11	71.37KB	Share
PGL	Preliminary Final Report	PRICE SENSITIVE	23/08/11	691.18KB	Share
PGL +AVE IMM	Progen Subsidiary Secures New Manufacturing Contracts	PRICE SENSITIVE	20/07/11	88.81KB	Share
PGL	PI-88 Receives Orphan Medicinal Product Designation	PRICE SENSITIVE	29/06/11	82.97KB	Share
PGL	PI-88 Phase III Update	PRICE SENSITIVE	23/06/11	85.58KB	Share
PGL	Appendix 3X - Woei-Jia Jiang		21/06/11	65.8KB	Share
PGL	Appendix 3Z - Paul Lin		21/06/11	212.09KB	Share
PGL	Progen Board and Senior Management Changes	PRICE SENSITIVE	16/06/11	88.81KB	Share
PGL	Completes Epi Pharmaceuticals Inc Formation and Reduces Risk	PRICE SENSITIVE	19/05/11	99.17KB	Share
PGL	Diversity Policy		16/05/11	158.68KB	Share
PGL	Progen Licensee Gains Approval for Phase III Clinical Trial	PRICE SENSITIVE	19/04/11	87.25KB	Share
PGL	Progen's PG11047 Clinical Study Completes Enrolment	PRICE SENSITIVE	06/04/11	94.08KB	Share
PGL	PG545 Presented at the AACR Annual Meeting	PRICE SENSITIVE	05/04/11	87.89KB	Share
PGL	Progen Enters Diabetes Collaboration with ANU	PRICE SENSITIVE	30/03/11	88.04KB	Share
PGL	Wholesale Investor Presentation		28/03/11	1.96MB	Share
PGL	Company Newsletter		23/03/11	965.3KB	Share
AAX +ABQ ADY CT1 AIV AKF APE DXC ARA AUK AZT AZX BBG BBL BIT BPO HPP BUL CCD CDD CLH CNH COI COK CPB CTO AQX DML DON DTG DVN EBG EMM ERA EXE FKP FLT GBP JNS GLL GPM AMN GWA HBS HIG QXR ICN IDL JIN KME LAU LDW MCC MNZ MST NHC OAK OCE OVT PAX PGL SKY PNA PNN PNR QRN RCT RFG RFX RPF RPX RUL SAP SDM SMR SUM SWL SXR TPA TPI TXN CR3 VBA VTG WBB WEC WHC WIG WTF WTP	Change of Share Registry Address		07/03/11	65.93KB	Share
PGL	Boardroom Radio Australia Interviews CEO Sue MacLeman		23/02/11	81.28KB	Share
PGL	Corporate Presentation Q1 2011		21/02/11	1.87MB	Share
PGL	Half Yearly Report and Accounts	PRICE SENSITIVE	16/02/11	438.79KB	Share
PGL	Progen Presents PG545 Data at Lorne Cancer Conference		11/02/11	85.37KB	Share
PGL	PG545 Data Published in British Journal of Cancer	PRICE SENSITIVE	03/02/11	99.89KB	Share
PGL	Progen Pharmaceuticals Granted US Patent	PRICE SENSITIVE	25/01/11	84.52KB	Share
PGL	Brisbane Flood Update		17/01/11	82.3KB	Share
PGL	JP Morgan Conference Presentation		12/01/11	1.82MB	Share
PGL	Appendix 3B		07/01/11	89.93KB	Share
PGL	Appendix 3B		07/01/11	187.85KB	Share
PGL	Trading Policy		31/12/10	63.69KB	Share
PGL	2010 Form 20-F Filed with US SEC		24/12/10	971.62KB	Share
PGL	Results of Meeting		16/11/10	185.67KB	Share
PGL	CEO's Address to Shareholders - 2010 AGM		16/11/10	1.08MB	Share
PGL	Chairman's Address to Shareholders - 2010 AGM		16/11/10	91.05KB	Share
PGL	PG545 to Enter Clinic in First In-Human Cancer Trial	PRICE SENSITIVE	15/11/10	92.27KB	Share
PGL	Progen Receives Purchase Order for PI-88 Trial Material	PRICE SENSITIVE	12/11/10	83.11KB	Share
PGL	Progen Closes US Office and Continues to Drive Strategy		29/10/10	92.74KB	Share
PGL	Progen presents at Life Science Investment Summit		19/10/10	917.23KB	Share
PGL	Progen Presents PG545 at TRX10 Conference		12/10/10	28.92KB	Share
PGL	Notice of Annual General Meeting/Proxy Form		08/10/10	265.79KB	Share
PGL	Annual Report to shareholders		30/09/10	6.42MB	Share
PGL	Progen Presents at Rodman and Renshaw Investor Conference		15/09/10	823.76KB	Share
PGL	Publication on PG11047		14/09/10	32.14KB	Share
PGL	Corporate Fact Sheet		10/09/10	604.52KB	Share
PGL	Progen Pharmaceuticals Licensee submits updated SPA to FDA	PRICE SENSITIVE	01/09/10	52.75KB	Share
PGL	Preliminary Final Report	PRICE SENSITIVE	27/08/10	745.71KB	Share
PGL	Progen Nasdaq Delisting Update		02/07/10	35.05KB	Share
PGL	Progen and Medigen sign License and Collaboration Agreement	PRICE SENSITIVE	30/06/10	32.66KB	Share
PGL	Trading Halt	PRICE SENSITIVE	30/06/10	511.55KB	Share
PGL	Progen granted muparfostat (PI-88) patent in Japan	PRICE SENSITIVE	28/06/10	29.86KB	Share
PGL	Progen Receives Delisting Notification from Nasdaq		24/06/10	76.67KB	Share
PGL	Company Newsletter		31/05/10	695.08KB	Share
PGL	Expiry of options		28/05/10	31.35KB	Share
PGL	Progen subsidiary secures manufacturing contract	PRICE SENSITIVE	27/05/10	31.52KB	Share
PGL	Company Secretary Resignation		24/05/10	28.47KB	Share
PGL	Progen granted Muparfostat (PI-88) patent in Europe	PRICE SENSITIVE	19/05/10	84.39KB	Share
PGL	Progen and Medigen sign non-binding Letter of Intent	PRICE SENSITIVE	30/04/10	82.42KB	Share
PGL	Progen subsidiary secures manufacturing contract	PRICE SENSITIVE	20/04/10	88.53KB	Share
PGL	Progen appoints directors to wholly-owned subsidiary		16/04/10	80.63KB	Share
PGL	Exclusive Licence Agreement Terminated	PRICE SENSITIVE	08/04/10	98.48KB	Share
PGL	Terms of New Chief Executive Officer Employment Contract		31/03/10	83.85KB	Share
PGL	Progen Appoints New Chief Executive Officer	PRICE SENSITIVE	29/03/10	87.91KB	Share
PGL	Progen's Roadshow Presentation		16/03/10	778.63KB	Share
PGL	Company Secretary Appointment		01/03/10	28.39KB	Share
PGL	Half Yearly Report and Accounts	PRICE SENSITIVE	26/02/10	465.69KB	Share
PGL	2009 Form 20-F Filed with US SEC		30/12/09	1.67MB	Share
PGL	Progen Appoints Dr. John Chiplin as Interim CEO		01/12/09	28.65KB	Share
PGL	Results of Meeting		01/12/09	67.45KB	Share
PGL	Director Resignations		26/11/09	31KB	Share
PGL	Becoming a substantial holder		24/11/09	2.7MB	Share
PGL	Legal Update - Settlement Reached	PRICE SENSITIVE	18/11/09	38.02KB	Share
PGL	Legal Update		09/11/09	27.45KB	Share
PGL	Notice of Annual General Meeting/Proxy Form		02/11/09	399.91KB	Share
PGL	Legal Update		22/10/09	26.05KB	Share
PGL	PG545 Preclinical Data to be Presented at Cancer Conference	PRICE SENSITIVE	14/10/09	33KB	Share
PGL	Annual Report to shareholders		30/09/09	1.97MB	Share
PGL	Legal Update		15/09/09	25.77KB	Share
PGL	PG11047 Phase 1 Study Completed	PRICE SENSITIVE	09/09/09	32.57KB	Share
PGL	Preliminary Final Report	PRICE SENSITIVE	31/08/09	685.62KB	Share
PGL	Commencement of Legal Proceedings		04/08/09	32.65KB	Share
PGL	Appendix 3X - Revised		03/08/09	43.62KB	Share
PGL	New Director Credentials		29/07/09	31.88KB	Share
PGL	Response to ASX Query re Appendices 3X		29/07/09	102.54KB	Share
PGL	Appendix 3X		27/07/09	10.82KB	Share
PGL	Appendix 3X		27/07/09	13.56KB	Share
PGL	Appendix 3X		27/07/09	10.81KB	Share
PGL	Chairman's Address to Shareholders		21/07/09	44.73KB	Share
PGL	Results of General Meeting		17/07/09	253.38KB	Share
PGL	Appendix 3X - Revised		17/07/09	43.12KB	Share
PGL	Becoming a substantial holder		14/07/09	61.63KB	Share
PGL	Becoming a substantial holder		14/07/09	81.71KB	Share
PGL	Appendix 3Z		09/07/09	44.15KB	Share
PGL	Appendix 3Z		09/07/09	12.39KB	Share

PGLNotice of Annual General Meeting/Proxy Form
31/10/11		670.8KB	Share
PGLAppendix 3Y
25/10/11		73.11KB	Share
PGLProgen Licensee Receives IND Approval in Korea for PI-88
17/10/11	PRICE SENSITIVE	92.63KB	Share
PGLNon-Executive Director Resignation
30/09/11		90.3KB	Share
PGLAnnual Report to shareholders
30/09/11		3.2MB	Share
PGLAppendix 3Y
29/09/11		70.54KB	Share
PGLLicensee Commences Recruitment, End of Settlement Agreement
26/09/11	PRICE SENSITIVE	239.88KB	Share
PGLClosure of PG545 Phase 1a Clinical Trial
20/09/11	PRICE SENSITIVE	93.7KB	Share
PGLAppendix 3Z
24/08/11		71.39KB	Share
PGLAppendix 3Z
24/08/11		71.37KB	Share
PGLPreliminary Final Report
23/08/11	PRICE SENSITIVE	691.18KB	Share
PGL +AVE IMMProgen Subsidiary Secures New Manufacturing Contracts
20/07/11	PRICE SENSITIVE	88.81KB	Share
PGLPI-88 Receives Orphan Medicinal Product Designation
29/06/11	PRICE SENSITIVE	82.97KB	Share
PGLPI-88 Phase III Update
23/06/11	PRICE SENSITIVE	85.58KB	Share
PGLAppendix 3X - Woei-Jia Jiang
21/06/11		65.8KB	Share
PGLAppendix 3Z - Paul Lin
21/06/11		212.09KB	Share
PGLProgen Board and Senior Management Changes
16/06/11	PRICE SENSITIVE	88.81KB	Share
PGLCompletes Epi Pharmaceuticals Inc Formation and Reduces Risk
19/05/11	PRICE SENSITIVE	99.17KB	Share
PGLDiversity Policy
16/05/11		158.68KB	Share
PGLProgen Licensee Gains Approval for Phase III Clinical Trial
19/04/11	PRICE SENSITIVE	87.25KB	Share
PGLProgen's PG11047 Clinical Study Completes Enrolment
06/04/11	PRICE SENSITIVE	94.08KB	Share
PGLPG545 Presented at the AACR Annual Meeting
05/04/11	PRICE SENSITIVE	87.89KB	Share
PGLProgen Enters Diabetes Collaboration with ANU
30/03/11	PRICE SENSITIVE	88.04KB	Share
PGLWholesale Investor Presentation
28/03/11		1.96MB	Share
PGLCompany Newsletter
23/03/11		965.3KB	Share
AAX +ABQ ADY CT1 AIV AKF APE DXC ARA AUK AZT AZX BBG BBL BIT BPO HPP BUL CCD CDD CLH CNH COI COK CPB CTO AQX DML DON DTG DVN EBG EMM ERA EXE FKP FLT GBP JNS GLL GPM AMN GWA HBS HIG QXR ICN IDL JIN KME LAU LDW MCC MNZ MST NHC OAK OCE OVT PAX PGL SKY PNA PNN PNR QRN RCT RFG RFX RPF RPX RUL SAP SDM SMR SUM SWL SXR TPA TPI TXN CR3 VBA VTG WBB WEC WHC WIG WTF WTPChange of Share Registry Address
07/03/11		65.93KB	Share
PGLBoardroom Radio Australia Interviews CEO Sue MacLeman
23/02/11		81.28KB	Share
PGLCorporate Presentation Q1 2011
21/02/11		1.87MB	Share
PGLHalf Yearly Report and Accounts
16/02/11	PRICE SENSITIVE	438.79KB	Share
PGLProgen Presents PG545 Data at Lorne Cancer Conference
11/02/11		85.37KB	Share
PGLPG545 Data Published in British Journal of Cancer
03/02/11	PRICE SENSITIVE	99.89KB	Share
PGLProgen Pharmaceuticals Granted US Patent
25/01/11	PRICE SENSITIVE	84.52KB	Share
PGLBrisbane Flood Update
17/01/11		82.3KB	Share
PGLJP Morgan Conference Presentation
12/01/11		1.82MB	Share
PGLAppendix 3B
07/01/11		89.93KB	Share
PGLAppendix 3B
07/01/11		187.85KB	Share
PGLTrading Policy
31/12/10		63.69KB	Share
PGL2010 Form 20-F Filed with US SEC
24/12/10		971.62KB	Share
PGLResults of Meeting
16/11/10		185.67KB	Share
PGLCEO's Address to Shareholders - 2010 AGM
16/11/10		1.08MB	Share
PGLChairman's Address to Shareholders - 2010 AGM
16/11/10		91.05KB	Share
PGLPG545 to Enter Clinic in First In-Human Cancer Trial
15/11/10	PRICE SENSITIVE	92.27KB	Share
PGLProgen Receives Purchase Order for PI-88 Trial Material
12/11/10	PRICE SENSITIVE	83.11KB	Share
PGLProgen Closes US Office and Continues to Drive Strategy
29/10/10		92.74KB	Share
PGLProgen presents at Life Science Investment Summit
19/10/10		917.23KB	Share
PGLProgen Presents PG545 at TRX10 Conference
12/10/10		28.92KB	Share
PGLNotice of Annual General Meeting/Proxy Form
08/10/10		265.79KB	Share
PGLAnnual Report to shareholders
30/09/10		6.42MB	Share
PGLProgen Presents at Rodman and Renshaw Investor Conference
15/09/10		823.76KB	Share
PGLPublication on PG11047
14/09/10		32.14KB	Share
PGLCorporate Fact Sheet
10/09/10		604.52KB	Share
PGLProgen Pharmaceuticals Licensee submits updated SPA to FDA
01/09/10	PRICE SENSITIVE	52.75KB	Share
PGLPreliminary Final Report
27/08/10	PRICE SENSITIVE	745.71KB	Share
PGLProgen Nasdaq Delisting Update
02/07/10		35.05KB	Share
PGLProgen and Medigen sign License and Collaboration Agreement
30/06/10	PRICE SENSITIVE	32.66KB	Share
PGLTrading Halt
30/06/10	PRICE SENSITIVE	511.55KB	Share
PGLProgen granted muparfostat (PI-88) patent in Japan
28/06/10	PRICE SENSITIVE	29.86KB	Share
PGLProgen Receives Delisting Notification from Nasdaq
24/06/10		76.67KB	Share
PGLCompany Newsletter
31/05/10		695.08KB	Share
PGLExpiry of options
28/05/10		31.35KB	Share
PGLProgen subsidiary secures manufacturing contract
27/05/10	PRICE SENSITIVE	31.52KB	Share
PGLCompany Secretary Resignation
24/05/10		28.47KB	Share
PGLProgen granted Muparfostat (PI-88) patent in Europe
19/05/10	PRICE SENSITIVE	84.39KB	Share
PGLProgen and Medigen sign non-binding Letter of Intent
30/04/10	PRICE SENSITIVE	82.42KB	Share
PGLProgen subsidiary secures manufacturing contract
20/04/10	PRICE SENSITIVE	88.53KB	Share
PGLProgen appoints directors to wholly-owned subsidiary
16/04/10		80.63KB	Share
PGLExclusive Licence Agreement Terminated
08/04/10	PRICE SENSITIVE	98.48KB	Share
PGLTerms of New Chief Executive Officer Employment Contract
31/03/10		83.85KB	Share
PGLProgen Appoints New Chief Executive Officer
29/03/10	PRICE SENSITIVE	87.91KB	Share
PGLProgen's Roadshow Presentation
16/03/10		778.63KB	Share
PGLCompany Secretary Appointment
01/03/10		28.39KB	Share
PGLHalf Yearly Report and Accounts
26/02/10	PRICE SENSITIVE	465.69KB	Share
PGL2009 Form 20-F Filed with US SEC
30/12/09		1.67MB	Share
PGLProgen Appoints Dr. John Chiplin as Interim CEO
01/12/09		28.65KB	Share
PGLResults of Meeting
01/12/09		67.45KB	Share
PGLDirector Resignations
26/11/09		31KB	Share
PGLBecoming a substantial holder
24/11/09		2.7MB	Share
PGLLegal Update - Settlement Reached
18/11/09	PRICE SENSITIVE	38.02KB	Share
PGLLegal Update
09/11/09		27.45KB	Share
PGLNotice of Annual General Meeting/Proxy Form
02/11/09		399.91KB	Share
PGLLegal Update
22/10/09		26.05KB	Share
PGLPG545 Preclinical Data to be Presented at Cancer Conference
14/10/09	PRICE SENSITIVE	33KB	Share
PGLAnnual Report to shareholders
30/09/09		1.97MB	Share
PGLLegal Update
15/09/09		25.77KB	Share
PGLPG11047 Phase 1 Study Completed
09/09/09	PRICE SENSITIVE	32.57KB	Share
PGLPreliminary Final Report
31/08/09	PRICE SENSITIVE	685.62KB	Share
PGLCommencement of Legal Proceedings
04/08/09		32.65KB	Share
PGLAppendix 3X - Revised
03/08/09		43.62KB	Share
PGLNew Director Credentials
29/07/09		31.88KB	Share
PGLResponse to ASX Query re Appendices 3X
29/07/09		102.54KB	Share
PGLAppendix 3X
27/07/09		10.82KB	Share
PGLAppendix 3X
27/07/09		13.56KB	Share
PGLAppendix 3X
27/07/09		10.81KB	Share
PGLChairman's Address to Shareholders
21/07/09		44.73KB	Share
PGLResults of General Meeting
17/07/09		253.38KB	Share
PGLAppendix 3X - Revised
17/07/09		43.12KB	Share
PGLBecoming a substantial holder
14/07/09		61.63KB	Share
PGLBecoming a substantial holder
14/07/09		81.71KB	Share
PGLAppendix 3Z
09/07/09		44.15KB	Share
PGLAppendix 3Z
09/07/09		12.39KB	Share

REFRESH

First 2 3 4 5 6

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.